1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
Session: Poster Abstract Session: Pneumococcal Vaccines
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • 2018 IDWEEK_Canada AMR Poster.pdf (1021.0 kB)
  • Background:

    Vaccines are an important factor in combating the growing global health issue of antimicrobial resistance. Pneumococcal conjugate vaccines (PCVs) have substantially reduced the burden of otitis media (OM) caused by S. pneumoniae, one of the largest causes of antibiotic prescriptions (Abx) in children under 5. The purpose of this study is to quantify the number of Abx avoided since the introduction of a national PCV program in Canada.

    Methods:

    We adapted a previously published forecasting model to estimate the reduction in OM cases in Canada since the introduction of PCVs in all routine provincial programs in 2005 through 2015 (the last year complete data was available). The impact of PCV on OM was modeled and compared to pre-PCV incidence to estimate net impact of the vaccine. We assumed that 90% of OM episodes were treated with an initial Abx given routine practice. All data was sourced from the published literature.

    Results:

    Over 10 years, PCVs were estimated to avert 3.7 million cases of OM in Canada. This corresponded to an estimated reduction of 3.3 million Abx, or 0.96 Abx avoided per infant vaccinated with PCV.

    Conclusion:

    PCVs have had a significant public health impact on reducing the burden of disease and Abx. While most of the PCV impact on reduction of Abx is due to reduction in OM cases, additional Abx reduction from prevention of other invasive and non-invasive pneumococcal diseases is of importance. Further research is necessary to understand the additional net benefit of reducing antibiotics across the disease spectrum given that reductions in net prescribing could avert further downstream resistance by other pathogens.

    Marie-Claude Breton, MPharm1, Raymond Farkouh, PhD2, Jelena Vojicic, MD3, Michele Wilson, MSPH4, Cheryl McDade, BA4 and Matt Wasserman, MSc5, (1)Pfizer Canada, Kirkland, QC, Canada, (2)Pfizer Inc, Collegeville, PA, (3)Pfizer Canada Inc., Kirkland, QC, Canada, (4)RTI Health Solutions, Research Triangle Park, NC, (5)Pfizer Inc., New York, NY

    Disclosures:

    M. C. Breton, Pfizer inc.: Employee , Salary .

    R. Farkouh, Pfizer: Employee , Salary .

    J. Vojicic, Pfizer: Employee and Shareholder , Benefits and stock and Salary .

    M. Wilson, Pfizer Inc: Consultant , Consulting fee .

    C. McDade, Pfizer Inc.: Consultant , Consulting fee .

    M. Wasserman, Pfizer: Employee , Salary .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.